BioSpace News Archive

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced the launch of its new global access program for FINTEPLA (fenfluramine) oral solution.

The Board of Directors of Terranueva Corporation (CSE: TEQ) (“Terranueva” or the “Company”) is pleased to announce the appointment of Jean-Luc Landry as Executive Chairman of the Board of Directors and Chief Executive Officer, Gérard Landry as President and Chief Operating Officer and Director and Sylvain Tremblay as Director.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally developed implantable tibial neuromodulation (TNM) device — a therapy designed to provide relief from symptoms of bladder incontinence.

World’s Largest Plastic Surgeon Organization Reveals 2020’s Most-Sought-After Procedures During Global Pandemic, Forecasts Members’ Rebound Year Ahead

Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug-linker PSARlink™ platform, announces today the completion of a €4 Million Seed financing round led by Elaia Partners and along with Pertinence Invest 2 (Sofimac Innovation advised by Mérieux Equity Partners

NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Hijaz Haris, as its Vice President of Marketing

VBI Vaccines Inc. ( Nasdaq: VBIV ) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, President and Chief Executive Officer, and David E. Anderson, Ph.D., Chief Scientific Officer, will discuss VBI’s coronavirus vaccine candidates in a virtual, analyst-led biotech investor summit hosted by National Securities Corporation

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has completed enrollment in its one hundred patient Motiva Mia® case series in Costa Rica.

Dyno Therapeutics , a biotech company applying artificial intelligence (AI) to gene therapy, today announced that it will deliver three oral presentations and an Industry Symposium at the 24 th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) being held as a virtual meeting on May 11–14, 2021.

Worldwide License to AAV sL65 Capsid, Novel Liver-Targeting Capsid, to Support Development of CANbridge Gene Therapy Programs for Fabry disease, Pompe disease and Options for two Additional Indications Option to Exclusive License for LB-001, Investigational Gene Editing Treatment for Methylmalonic Acidemia, in Greater China